Shattuck Labs, Inc. (STTK)

Shattuck Labs is a clinical-stage biotech developing bifunctional fusion proteins targeting immuno-oncology and autoimmune disease, with its lead pipeline assets representing a differentiated mechanism that has driven unanimous analyst Buy coverage. The stock trades at a ~92% discount to the consensus mean price target of $14.25, reflecting significant optionality if upcoming clinical data readouts validate efficacy. The primary risk is binary clinical trial outcomes — a pipeline setback at this pre-revenue stage could be severely dilutive to the share price.

• Clinical data readouts from lead bifunctional fusion protein programs in immuno-oncology that could de-risk the pipeline and act as a near-term re-rating event.
• Potential partnership or licensing deal driven by differentiated pipeline assets, which could provide non-dilutive capital and validate the platform technology.
• Continued EPS beat trajectory in upcoming quarterly reports signaling disciplined cash burn management and extended runway, reinforcing management credibility.

• Binary clinical risk: a Phase 1/2 trial failure in the lead oncology or autoimmune program could wipe out a substantial portion of the ~$7.42 share price given the company has no revenue backstop.
• Cash burn and dilution risk: as a pre-revenue biotech, continued operating losses require periodic equity raises that could dilute existing shareholders, especially if capital markets tighten.
• Competitive landscape risk: larger, better-funded biotechs and pharma companies pursuing similar bifunctional or bispecific modalities could render Shattuck's platform less differentiated, reducing partnership leverage and peak sales potential.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →